Strong Growth and Market Performance During Q3 2024
Essity has released its interim report for the third quarter of 2024, showcasing profitable growth and enhanced market shares across its various sectors.
Key Financial Highlights
In the third quarter, Essity experienced a slight decrease in net sales, down by 2.2% to SEK 36,274 million compared to the previous year. However, the company achieved organic growth of 1.9%, with volume contributing positively and a modest decline from price adjustments. When restructuring impacts are excluded, the organic growth figures show a more robust increase of 3.4%.
Remarkably, EBITA soared by 47%, reaching SEK 5,130 million, reflecting the company’s operational strength. Even when excluding items affecting comparability (IAC), EBITA remained strong, only decreasing by 1%. Furthermore, the EBITA margin, when not accounting for IAC, modestly rose to 14.1%.
Return on Capital Employed (ROCE) experienced a significant uptick to 17.8%, reinforcing Essity's efficient capital usage. The company’s operating cash flow saw a 7% improvement, amounting to SEK 6,453 million, which has allowed for a reduction in net debt.
CEO's Insight on Business Growth
Magnus Groth, the company’s President and CEO, emphasized the quarter's strong earnings paired with record-high cash flow during his comments on the report. He noted that Essity’s commitment to growth has been instrumental in securing higher volumes and capturing market shares worldwide.
Volume and Market Expansion
Every day, Essity enhances the hygiene and health of a billion individuals across various regions. This commitment remains essential despite economic pressures. Notably, the company reported increased volumes in all categories, marking significant success even amidst broader economic challenges.
The Health & Medical sector, particularly, demonstrated strong growth dynamics, especially in European and Latin American markets. Products like TENA Pants in Incontinence Care have contributed considerably to both volumes and profit margins, with positive feedback from both caregivers and patients. Furthermore, wound care products under the Leukoplast and Cutimed brands saw substantial growth, underpinning Essity's strong market presence.
Operational Achievements
Essity's well-rounded profitability can be attributed to improvements across all business areas. Higher sales volumes and effective product mix strategies have played critical roles in enhancing earnings. Despite experiencing lower costs for goods sold, the company has maintained rigorous price discipline, allowing for increased sales prices relative to earlier periods.
Notably, the company has successfully realized over SEK 1 billion in cost savings this year through relentless efficiency improvements, showcasing its strategic focus.
Record Cash Flow Generation
During the quarter, strong cash flow generation enabled Essity to further diminish net debt levels. The company continues its share buyback program, with approximately 4 million Class B shares repurchased thus far, reflecting its robust financial health and shareholder commitment.
Future Outlook and Vision
Looking ahead, Essity aims to remain at the forefront of the hygiene and health markets, focusing on innovation, sustainability, and operational efficiency to pursue its mission of global leadership. The impending Capital Markets Day, set to occur in December, will offer deeper insights into the company's strategic vision and operational advancements.
Magnus Groth anticipates sharing this valuable information with stakeholders during the presentation, reinforcing the company's commitment to transparency and growth.
Frequently Asked Questions
What were the notable financial highlights for Essity in Q3 2024?
Essity reported a 2.2% decrease in net sales at SEK 36,274 million but achieved a 1.9% organic growth, with EBITA increasing by 47% to SEK 5,130 million.
How did the company perform in terms of market share?
Despite challenging global economic conditions, Essity gained higher market shares across its categories, especially in health and medical products.
What initiatives has Essity taken to improve profitability?
The company focused on cost savings, efficient operations, and maintaining price discipline despite lower costs for goods sold, achieving over SEK 1 billion in savings.
How is Essity's cash flow situation?
Essity generated strong operational cash flow in Q3 2024 and continued to reduce net debt while executing a share buyback program.
What are Essity's future plans?
Essity plans to strengthen its position in the hygiene and health markets through innovation and efficiency, with insights to be shared during its upcoming Capital Markets Day.
